Aethlon Medical, Inc. — Form 10-Q Summary
Business context and period: Aethlon develops medical devices based on its ADAPT plasma-filtration platform, including the Hemopurifier. This report covers the three months ended June 30, 2013, the first quarter of fiscal 2014. The company’s reported revenue came from government contract work; it had not generated significant commercial revenue or operating profit.
Financial performance and position
| Metric | Quarter ended June 30, 2013 | Prior-year quarter |
|---|---|---|
| Revenue | $195,596 | $216,747 |
| Operating expenses | $979,394 | $1,207,553 |
| Operating loss | $783,798 | $990,806 |
| Net loss | $303,498 | $1,016,784 |
| Net cash used in operations | $221,621 | $320,239 |
| Financing cash provided | $128,000 | $772,390 |
- Cash was $31,653 at June 30, down from $125,274 at March 31, 2013. Working capital deficit was approximately $8.95 million; total assets were $195,243 and total current liabilities were $9.02 million.
- Current liabilities included $2.26 million of convertible notes, net of discounts, and $2.89 million of derivative liabilities. Stockholders’ deficit was $8.82 million.
- Operating expenses were about 5.0 times revenue; the filing does not report a gross margin. The $609,125 gain from a decrease in derivative fair value materially reduced the reported net loss and is a non-cash item.
Material changes and notable items
- Revenue declined about 9.8% year over year. Operating expenses fell 18.9%, mainly from lower professional fees and payroll-related costs; general and administrative expenses increased.
- Net loss narrowed substantially, reflecting lower operating expenses and lower interest and debt-discount amortization, in addition to the derivative fair-value gain.
- The company issued $128,000 of equity units during the quarter and converted debt and accrued amounts into shares. Shares outstanding increased to 182.6 million at June 30 from 173.7 million at March 31. The filing reports 190.0 million shares outstanding as of August 13.
Outlook, risks and contingencies
- The FDA approved an IDE on June 25, 2013, allowing a U.S. feasibility study of the Hemopurifier in ten HCV-infected end-stage renal disease patients. Further trials and regulatory approvals are needed before U.S. commercialization; success is not assured.
- The DARPA contract generated the quarter’s revenue. DARPA exercised year two, while years three through five remain optional. A related Battelle subcontract was expected to generate revenue in fiscal 2014, subject to Battelle’s direction. In July 2013, Aethlon invoiced and collected $404,362 in DARPA milestone payments and invoiced Battelle for $20,340.
- Management cited substantial doubt about the company’s ability to continue as a going concern. It stated that cash and funds raised after quarter-end were insufficient for the next 12 months and that continued operations depend on additional financing. A broker-dealer engagement is on a best-efforts basis, with no assurance financing will be completed on acceptable terms or at all.
- After quarter-end, the company borrowed $400,000 from two directors under short-term notes, completed a $100,000 equity financing, and issued shares in further debt conversions. These transactions provide near-term funds but involve repayment, potential conversion and dilution risk.
- Numerous notes were past due or in default, and accrued interest was substantial. The filing gives differing totals for past-due principal in different sections; investors should verify the amount and status of each obligation. The company also had $437,800 accrued for registration-related liquidated damages.
- Gemini Master Fund litigation remained in late discovery with no trial date. The company said an adverse outcome could harm operations and dilute shareholders.
- Management concluded disclosure controls and procedures were not effective at quarter-end. The filing reports no material change in internal control over financial reporting during the quarter.
- No formal earnings guidance was provided. Management expected continued losses and negative cash flows and identified financing, clinical and regulatory progress, patent protection, market acceptance and DARPA contract options as key uncertainties.
Important facts for investors to verify
- Available cash, subsequent financing proceeds, near-term cash needs and the company’s ability to fund operations and clinical-trial costs.
- Amounts, maturities, default terms and conversion provisions of past-due debt, including the differing past-due principal totals disclosed in the filing.
- Timing, enrollment and results of the U.S. feasibility study, and the requirements for any subsequent pivotal studies or market approval.
- Future DARPA milestone awards and options, and the scope and revenue potential of the Battelle subcontract.
- Potential dilution from outstanding warrants, options, convertible debt and subsequent share issuances, as well as the status and exposure of the Gemini litigation.